BridgeBio Oncology Therapeutics Inc. (BBOT) is a Healthcare stock trading at $7.61 (as of 2026-06-18), with a market capitalization of $643.26M and a trailing P/E of -0.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.